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Abstract
Background—It is estimated half of acute coronary syndrome (ACS) patients have one or more 
associated comorbid conditions.
Aims—Aims were to: 1) examine the prevalence of comorbid conditions in patients presenting to 
the emergency department with symptoms suggestive of ACS; 2) determine if comorbid 
conditions influence ACS symptoms; and 3) determine if comorbid conditions predict the 
likelihood of receiving an ACS diagnosis.
Methods—A total of 1064 patients admitted to five emergency departments were enrolled in this 
prospective study. Symptoms were measured on presentation to the emergency department. The 
Charlson Comorbidity Index (CCI) was used to evaluate group differences in comorbidity burden 
across demographic traits, risk factors, clinical presentation, and diagnosis.
Results—The most prominent comorbid conditions were prior myocardial infarction, diabetes 
without target organ damage, and chronic lung disease. In younger ACS patients, higher CCI 
predicted less chest pain, chest discomfort, unusual fatigue and a lower number of symptoms. In 
older ACS patients, higher CCI predicted more chest discomfort, upper back pain, abrupt 
symptom onset, and greater symptom distress. For younger non-ACS patients, higher CCI 
predicted less chest pain and symptom distress. Higher CCI was associated with a greater 
likelihood of receiving an ACS diagnosis for younger but not older patients with suspected ACS.
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Conclusions—Younger patients with ACS and higher number of comorbidities report less chest 
pain, putting them at higher risk for delayed diagnosis and treatment since chest pain is a hallmark 
symptom for ACS.
Keywords
Acute coronary syndrome; comorbidities; symptoms; age; cardiovascular conditions; emergency 
medicine
Introduction
It is estimated that nearly half of patients with acute coronary syndrome (ACS) have one or 
more comorbid conditions such as history of myocardial infarction (MI), diabetes, chronic 
lung disease, chronic kidney disease, peripheral vascular disease, and cerebrovascular 
disease.1,2 However, clinical practice guidelines for patients with coronary heart disease 
(CHD) were developed for the treatment of a single chronic condition and may not be 
successful for the management of CHD in the presence of multiple comorbidities.3 In 
addition, individuals with multiple comorbid conditions are often excluded from randomized 
clinical trial populations,4,5 reducing the pragmatic application of research findings into 
clinical practice.
Comorbid conditions have been linked to demographic and clinical characteristics of ACS 
patients. Fassa et al.6 assessed data from 19,496 ACS patients in the Acute Myocardial 
Infarction in Switzerland (AMIS) Plus registry and found higher Charlson Comorbidity 
Index (CCI) scores were associated with increased age, female sex, hypertension, 
dyslipidemia, obesity, and lower current cigarette use. Higher CCI scores were also 
associated with fewer “typical symptoms” of chest pain and dyspnea. In a study of 2972 
American patients hospitalized with acute MI, Chen et al.7 examined both cardiovascular 
and non-cardiovascular comorbid conditions. The most common cardiac comorbidity was 
hypertension (75%). Chronic kidney disease (22%) was the most common noncardiac 
comorbid condition. Patients with multiple comorbid conditions were significantly more 
likely to be older, female, unmarried, have a history of prior MI, and present with a non-ST 
elevation MI.
The complexity of clinical decision-making in the presence of multiple comorbidities and 
the lack of explicit guidelines has been linked to poorer adherence to treatment protocols and 
worse outcomes for ACS patients.3,4,6,8 Under-usage of medication and standard-of-care 
procedures due to the unknown effects of certain therapies for patients with multiple 
comorbidities has been reported (e.g. percutaneous coronary interventions, dual antiplatelet 
therapy).3,4,6,8 Worse in-hospital and one year outcomes as well as increased mortality rates 
have also been reported in ACS patients with multiple co-morbidites.2,4,6,7,9,10
Limited research has investigated the relationships between multiple comorbid conditions, 
CHD risk factors, clinical presentation, and diagnosis among patients presenting to the 
emergency department (ED) with symptoms prompting an evaluation for ACS. Available 
data are insufficient to provide scientific support for evidence-based care of patients afflicted 
by multiple comorbidities. Therefore, the aims of this study were to: 1) examine the 
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prevalence of CHD risk factors and comorbid conditions in a sample of patients presenting 
to the ED with symptoms suggestive of ACS; 2) determine if comorbid conditions influence 
symptoms; and 3) determine if comorbid conditions predict the likelihood of receiving an 
ACS diagnosis.
Methods
Study design
The study was a descriptive, prospective study whose main aim was to explore the influence 
of sex on symptoms suggestive of ACS.11 The investigation conforms with the principles 
outlined in the Declaration of Helsinki.12 The Institutional Review Board (IRB) from the 
sponsoring institution and each clinical data collection site gave approval for the study prior 
to launch. Each IRB approved a waiver of initial consent for electronic screening of patients 
and to collect initial symptom data prior to enrollment. A waiver of initial consent was 
granted since the main study aim was to evaluate symptoms on presentation to the ED and 
because the emergent nature of patients presenting with possible ACS precluded the 
provision of immediate informed consent.13 All patients gave written, informed consent 
prior to enrollment in the study when they were stable and had been transferred to a private 
examination room.
Study setting and population
Individuals presenting to the ED with symptoms triggering a cardiac evaluation, ≥21 years 
old, fluent in English, and who arrived by private transportation or emergency medical 
services were eligible. Patients were excluded if they had an exacerbation of heart failure 
(brain natriuretic peptide >500pg/ml), were transferred from a hemodialysis facility, were 
referred for evaluation of a dysrhythmia, or had cognitive impairment, defined as the 
inability to understand and provide written informed consent. Enrollment occurred between 
January 2011 and December 2014 in five EDs in the Midwest, West, and Pacific Northwest 
regions of the USA. The centers included four academic medical centers and a large, referral 
community medical center.14
Study protocol
Study research staff completed the ACS Symptom Checklist shortly after the patient was 
evaluated in triage. The symptom checklist was completed by the patient if they were able or 
by research staff if the patient could not read or was otherwise unable to complete the 
checklist. Research staff were blinded to the patient’s final diagnosis. Symptoms were 
assessed within 15 min of ED presentation in most cases and enrollment occurred between 
07:00 h and 23:00 h every day of the week. Research staff were unavailable between the 
hours of 23:00 and 07:00. Patients triggering a cardiac workup were approached by the 
research staff for enrollment after they were deemed stable by the primary nurse or 
physician and had been transferred to a private examination room in either the ED or 
hospital unit. The study purpose was explained, and once the patient provided written 
informed consent, additional clinical and individual characteristics were recorded by 
research staff. Initial symptom data were destroyed if the patient declined to participate. Of 
eligible patients, 28.7% declined to participate, citing fatigue, anxiety, or lack of interest.
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Measures
CCI—Comorbid conditions were measured with the CCI, a 19-item weighted index which 
has been used extensively to quantify illness risk and risk of mortality associated with 
comorbid conditions.15,16 Higher scores represent a greater burden of disease. Studies have 
demonstrated that the CCI is a valid measure for predicting disability and death following 
ischemic stroke and heart disease.16 Correlations with mortality, disability, hospital 
readmission and length of stay have ranged from 0.35 to 0.93 (p<0.001).17,18
ACS Symptom Checklist—Symptoms were measured with the validated 13-item ACS 
Symptom Checklist. The checklist was derived from the Symptoms of Acute Coronary 
Syndromes Index (SACSI). The SACSI, a reliable (Cronbach’s α=0.81)19 and valid (content 
validity indexes of 0.88 and 0.94) instrument, was tested in previous studies.20,21 
Participants indicate whether the symptom is present or absent on presentation to triage. 
Symptoms not appearing on the checklist can be recorded in a blank space marked “other”. 
For this study, symptoms were measured dichotomously on ED admission (yes/no). Each 
symptom is analyzed individually and there is no summary score.
ACS Patient Information Questionnaire—The questionnaire includes patient-reported 
information on demographic and clinical variables including CHD risk factors. The 
questionnaire was designed using the standardized reporting guidelines for studies 
evaluating ED patients with potential ACS.22 The criteria were established by the 
Multidisciplinary Standardized Reporting Criteria Task Force and are supported by the 
Society for Academic Medicine, the American College of Emergency Physicians, the 
American Heart Association, and the American College of Cardiology. The purpose of the 
questionnaire is to establish standardized ED reporting criteria that will facilitate study 
comparisons and meta-analyses. CHD risk factors included on the tool are high blood 
pressure, family history of heart disease or sudden cardiac death, diabetes, tobacco use, 
hypercholesterolemia, cocaine or amphetamine use, kidney disease, and obesity.
Duke Activity Status Index—Functional status was measured with the Duke Activity 
Status Index (DASI), a 12-item instrument that measures functional capacity.23 Scores range 
from 0 to 58.2, with higher scores representing better physical functioning. Items are 
weighted to reflect metabolic energy expenditure and correlate highly with peak VO2 (r = 
0.80, p < 0.0001)23 in patients with ACS,24 ischemic heart disease,25 heart failure,26 and 
revascularization procedures.27
Data analyses
Data analyses were performed using SPSS, Version 22.0 (IBM Corp, Armonk, NY, USA) 
and SAS, Version 9.4 (SAS®, Cary, NC, USA). Significance was set at p<0.05 for all 
statistical procedures. Frequency distributions were assessed for all variables. Fisher’s exact 
tests were used to test differences in the frequencies of individual comorbid conditions 
between ACS and non-ACS diagnosed patients. After stratifying by ACS diagnosis, general 
linear modeling was used to test the differences in mean CCI scores by demographic, 
clinical characteristics, and CHD risk factors while adjusting for age. General (for 
continuous variables) and generalized linear modeling with a logit link function (for 
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categorical variables) were used to determine if comorbidity scores could predict an ACS 
diagnosis and ACS symptom characteristics controlling for age, sex, race, tobacco use 
(never, former, current user), DASI score, high blood pressure (yes/no), and recruitment site. 
Type of ACS diagnosis was included as a covariate for models predicting symptoms among 
ACS patients. Covariates were selected for the model based on whether they were 
significantly related to CCI scores in the bivariate models and/or if the variables were 
significantly related to the outcome measure in multivariate models. Interaction terms 
between age and comorbidity score were included in all models to produce age-specific 
estimates. Age and comorbidity scores were included in the models as continuous variables 
and odds ratios (for dichotomous variables) or unstandardized beta coefficients (for 
continuous variables) and were calculated at 10 year intervals (40, 50, 60, 70, and 80 years 
old) representing the effect of a one unit change in CCI score on the outcome for a person of 
that age. Comorbidity data were missing for three participants, therefore the final sample 
size for the analyses was 1061.
Results
Demographic and clinical characteristics of the sample by diagnosis
Demographic and clinical characteristics for patients discharged with an ACS or non-ACS 
diagnosis are summarized in Table 1. The sample was predominately male (n=662, 62.4%) 
and non-Hispanic White (n=737, 69.5%). The majority of patients had private insurance 
through an employer (n=330, 31.1%) or Medicare (n=348, 32.8%). There was a range of 
education and income levels; patients most frequently reported having some college 
education or higher (n=700, 66%) and lower or middle income levels (n=632, 59.6%). The 
mean age was 61.7 ±11.9 years for ACS patients and 59.0±15.4 years for non-ACS patients. 
The most common ACS diagnosis was non-ST elevation MI (NSTEMI; n=251, 53.1%), 
followed by ST elevation MI (STEMI; n=118, 24.9%) and unstable angina (UA; n=104, 
22%). The majority of patients had multiple risk factors and some functional limitations.
Prevalence of CCI conditions by diagnosis
The most prominent comorbid conditions in patients presenting to the ED with potential 
ACS were previous history of MI, diabetes without target organ damage, and chronic lung 
disease (Table 2 and Figure 1). Eighteen of the 19 conditions listed on the CCI occurred in 
<25% of patients. The exception was a previous history of MI. Only three conditions varied 
by diagnosis; patients with ACS were more likely to have a history of prior MI and 
peripheral vascular disease. Non-ACS patients were more likely to have renal disease. The 
mean CCI score differed by diagnosis only for patients less than 50 years old.
Comorbid conditions and demographic and clinical characteristics
As expected, the mean number of comorbid conditions increased with age (Table 1). CCI 
scores differed by type of insurance for patients with and without ACS. Patients with 
government sources of health insurance (Medicare, Medicaid, Social Security Disability, and 
Veterans Affairs) had more comorbid conditions compared with those with private insurance 
or those who were uninsured. For those ruled-out for ACS, patients with less than a high 
school diploma and with a reported income less than US$20,000 per year had higher mean 
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CCI scores. Mean CCI scores were highest for patients with NSTEMI and unstable angina 
compared with STEMI. For both ACS and non-ACS patients, higher CCI scores were 
associated with hypertension and functional limitations. Notably, former tobacco users had 
higher CCI scores compared with current users. Obesity was associated with a higher CCI 
score in patients with ACS.
Comorbidity score predicts ACS diagnosis in younger patients
A multivariate model was constructed to determine if CCI scores would predict an ACS 
diagnosis while controlling for age and other established CHD risk factors (Table 3 and 
Figure 2). Using the regression model, odds ratios were calculated to show how a one unit 
change in CCI score affected the odds of an ACS diagnosis when a patient was either 40, 50, 
60, 70, or 80 years old. CCI scores were found to be predictive of an ACS diagnosis for 
younger patients only (40–50 years old). Thus, the presence of comorbid conditions 
increased the likelihood that younger patients (under age 60) presenting to the ED with ACS 
symptoms would receive a final ACS diagnosis.
Predicting symptoms for ACS patients by comorbidity scores
Multivariate modeling was conducted to assess the impact of CCI scores on symptom 
presentation for ACS and non-ACS patients (Table 3 and Figure 2). Odds ratios for 
dichotomous outcomes and unstandardized beta coefficients (b) for continuous outcomes are 
presented to show how a one unit change in CCI score affected the odds or changed the 
mean score of the outcome when a patient was either 40, 50, 60, 70, or 80 years old. For 
younger ACS patients, more comorbid conditions meant that several symptoms were less 
likely to be reported. Younger patients with ACS were less likely to present with chest 
discomfort, chest pain, and unusual fatigue as comorbidity scores increased. Greater 
comorbidity burden also meant that younger ACS patients reported fewer symptoms overall. 
For middle-aged ACS patients, more comorbid conditions meant that arm pain and 
indigestion were reported less. For older patients with ACS, more comorbid conditions were 
linked to more reports of chest discomfort and upper back pain. Also, having more comorbid 
conditions was related to a greater likelihood of having an abrupt onset of symptoms and 
greater distress from symptoms for older patients.
Predicting symptoms for non-ACS patients by comorbidity score
For patients who received a non-ACS diagnosis, greater comorbidity burden was only linked 
to two symptom characteristics. For younger patients ruled-out for ACS, greater comorbidity 
burden was linked to less chest pain. More comorbidities were also connected to less distress 
from symptoms for younger non-ACS patients (Table 3 and Figure 2).
Discussion
There were few differences (three of 19) in the number of comorbid conditions between 
those ruled-in versus those ruled-out for ACS. Presence of comorbid conditions as measured 
by the CCI in this study provided little additional information that could contribute to risk 
stratification on arrival to the ED. Traditional risk factors have also performed poorly in 
prior ED studies, leading clinicians to perform 12-lead electrocardiograms and cardiac 
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biomarkers on all potential ACS patients.28,29 Consistent with prior research, the CCI 
appears to be a valid measure of the impact of comorbid conditions on mortality but 
unfortunately does not appear to be a robust measure of the impact of comorbid conditions 
on ACS risk stratification, incidence of disease, or clinical presentation. The finding that a 
previous history of MI was the most prevalent comorbid condition in this population was not 
surprising. Prior findings have also supported rates of prior MI in the 60% range.7 Diabetes 
was reported by almost a quarter of patients. In addition to being a comorbid condition, 
diabetes is also a strong CHD risk factor and so these findings add additional evidence from 
a large heterogeneous population to what is already known about the risks of this disease. 
The finding that chronic obstructive pulmonary disease (COPD) was the third highest 
reported comorbidity for patients with and without ACS is noteworthy and may be related to 
smoking since smoking is an important risk factor for both CHD and COPD.
Those in a lower socioeconomic class had more comorbid conditions, which is consistent 
with prior reports30 and may reflect reduced access to health care. Patients with NSTEMI 
and UA had a higher number of comorbid conditions and CHD risk factors (tobacco use, 
hypertension, hypercholesterolemia) than those with STEMI. This was not explained by age 
since even those patients with NSTEMI and UA under age 50 had more comorbid 
conditions. Obese patients with ACS (but not those without ACS) had significantly higher 
mean CCI scores. This adds more evidence of the CHD risk that has been linked to obesity 
in the last decade. Patients receiving government sponsored health insurance and older 
patients had higher mean CCI scores as expected given that these individuals are eligible for 
Medicare and that older individuals have more comorbid conditions. The finding that an 
ACS diagnosis was more likely with higher comorbidities in younger but not older patients 
is noteworthy, particularly for males who develop ACS at an earlier age compared with 
women.31 Finally, consistent with our findings, Scheuermeyer et al.32 found that many 
symptoms were less likely for younger ACS patients with comorbidities, which could 
increase risk of pre-hospital delay and complicate patient triage.
The prevalence of multiple comorbid conditions is increasing in the American population 
due to improvements in acute care and primary prevention strategies that have increased life 
expectancy.33 In addition, multiple comorbidities are associated with higher mortality rates 
and health care utilization.7 In a cohort of Danish patients, Schmidt et al.34 found that the 
odds of death at 30 days post MI increased from 1.96 (95% confidence interval (CI), 1.83–
2.11) to 3.89 (95% CI, 3.58–4.24) for those with “normal” comorbid conditions compared 
with those with “severe” comorbid conditions. A portion of the increase in death rates with 
older age may be explained by less aggressive treatment or palliative care approaches,35 but 
comorbidities still pose a threat to patients with ACS.
Strengths
Much of the data published on comorbid conditions in patients with ACS have been 
collected in Europe.1,2,6,36 Far fewer studies have been completed in the USA, where it 
appears that rates of multiple comorbidities are higher. In addition, symptoms reported 
directly by patients were recorded soon after presentation to the ED. The availability of self-
report of active symptoms eliminated recall bias, enhancing the internal validity of the 
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findings. The inclusion of a large heterogeneous sample of patients resulted in a well-
powered study facilitating the detection of small effects. Our sample (30.1% minority 
members) was representative of the US population and there were minimal baseline 
differences between patients with and without ACS. Finally, we adjusted for factors well-
known to affect symptoms and comorbidity burden such as age and functional status.
Limitations
Sampling bias is a potential limitation to the study. Patients whom ED nurses and physicians 
deemed to be at risk for ACS were included in the study. Hence, we may have missed 
patients if the patient was not evaluated for ACS. In order to include enough patients who 
ruled-in for ACS, we targeted patients with an elevated troponin level and therefore the 
sample may not be representative of all those presenting to triage with possible ACS 
symptoms. Patients were only enrolled from 07:00 h to 23:00 h. Therefore, findings may not 
be generalizable to patients arriving at the ED from 23:00 h to 07:00 h. There was potential 
selection bias as 28.7% of patients approached declined to participate in the study. This is 
not surprising due to the high acuity rates in the ED setting.
Conclusions
Comorbidities affect symptoms for patients presenting to the ED with suspected ACS and 
this relationship varies by age. Comorbidities may present a unique challenge in younger 
patients because they are less likely to report chest symptoms. More studies are needed to 
better understand the impact of comorbidities on ACS symptom presentation and risk 
stratification in the ED. Awareness of these findings could help in getting more individuals 
screened for CHD and risk stratified accurately, potentially reducing the incidence of ACS.
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Implications for practice
• Our research did not support use of the Charlson Comorbidity Index for 
assessing acute coronary syndrome risk stratification, incidence of disease, or 
clinical presentation in the emergency department.
• Nurses should be alert to the risk of acute coronary events among patients 
with chronic obstructive pulmonary disease and diabetes as nearly 20% and 
30% (respectively) of patients in our sample had these conditions.
• Nurses should be aware of a potentially higher number of comorbid 
conditions among patients with non-ST elevation myocardial infarction and 
unstable angina compared with ST elevation myocardial infarction. There 
may be a propensity to delay evaluation or treatment of non-ST elevation 
myocardial infarction/unstable angina patients since both these conditions are 
considered to be less life-threatening than ST elevation myocardial infarction.
• Emergency department nurses and nurses evaluating patients with suspected 
acute coronary syndrome should be aware that younger patients with 
comorbid conditions may have a higher likelihood of receiving an acute 
coronary syndrome diagnosis.
• Emergency department nurses and nurses evaluating patients with suspected 
acute coronary syndrome should know that younger patients with comorbid 
conditions may be less likely to present with classic acute coronary syndrome 
symptoms and may present with fewer acute coronary syndrome symptoms 
overall.
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Figure 1. 
Frequency of Charlson Comorbidity Index scores by diagnosis.
ACS: acute coronary syndrome.
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Figure 2. 
Predicted percentages and means of ACS diagnosis and type, number, and distress of 
symptoms by comorbidity scores for given ages. Example CCI scores of 0 and 5 were 
selected to represent the likelihood of the outcome for an example patient with either a low 
or high comorbidity score. Results are listed by age group due to significant interactions 
between CCI scores and age. Models adjusted for gender, race, functional status, tobacco 
use, hypertension and recruitment site. ACS models were adjusted for type of ACS 
diagnosis.
*Denotes key findings.
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ACS: acute coronary syndrome; CCI: Charlson Comorbidity Index.
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Table 2
Prevalence of CCI conditions and total CCI score by final ACS diagnosis.
CCI conditions Weight ACS (n=473) Non-ACS (n=588) p-value
n (%) n (%)
History of prior myocardial infarction 1 323 (68.4) 153 (26.1) <0.001
Diabetes without target organ damage 1 119 (25.2) 130 (22.1) 0.244
Chronic lung disease – asthma 1 88 (18.6) 137 (23.3) 0.070
Peripheral vascular disease 1 45 (9.5) 30 (5.1) 0.008
Cerebrovascular disease –stroke 1 37 (7.8) 55 (9.4) 0.443
Connective tissue disease – lupus 1 31 (6.6) 36 (6.1) 0.801
Dyspnea 1 24 (5.1) 24 (4.1) 0.460
Mild liver disease 1 15 (3.2) 24 (4.1) 0.513
Peptic ulcer disease 1 13 (2.8) 27 (4.6) 0.144
Dementia 1 4 (0.8) 13 (2.2) 0.089
Malignant neoplasm 2 36 (7.6) 53 (9.0) 0.437
Diabetes with target organ damage 2 26 (5.5) 37 (6.3) 0.604
Moderate to severe renal disease 2 14 (3.0) 34 (5.8) 0.037
Lymphoma 2 6 (1.3) 6 (1.0) 0.775
Hemiplegia 2 4 (0.8) 4 (0.7) 1.000
Leukemia 2 3 (0.6) 6 (1.0) 0.739
Moderate to severe liver disease 3 1 (0.2) 3 (0.5) 0.633
Metastatic solid tumor 6 6 (1.3) 15 (2.6) 0.183
Acquired immunodeficiency syndrome 6 2 (0.4) 3 (0.5) 1.000
M (SD) M (SD) p-value
Mean score 2.0 (1.7) 1.7 (2.0) 0.049
< 50 years old 1.5 (1.5) 1.0 (1.8) 0.034
50–59 years old 1.7 (1.7) 1.7 (1.9) 0.812
60–69 years old 2.2 (1.7) 1.8 (1.8) 0.080
70+ years old 2.3 (1.8) 2.5 (2.2) 0.377
Bold p-values are statistically significant. Fisher’s exact tests used for categorical variables and t-tests used for comparisons of means.
CCI: Charlson Comorbidity Index; ACS: acute coronary syndrome.
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ne
 u
ni
t i
nc
re
as
e 
in
 c
om
or
bi
di
ty
 sc
or
e.
 O
dd
s r
at
io
s a
re
 re
po
rte
d 
fo
r c
at
eg
or
ic
al
 v
ar
ia
bl
es
. U
ns
ta
nd
ar
di
ze
d 
be
ta
 c
oe
ffi
ci
en
ts 
(b)
 ar
e l
ist
ed
 fo
r 
co
n
tin
uo
us
 v
ar
ia
bl
es
. R
es
ul
ts 
ar
e 
lis
te
d 
by
 a
ge
 d
ue
 to
 si
gn
ifi
ca
nt
 in
te
ra
ct
io
ns
 b
et
w
ee
n 
CC
I s
co
re
s a
nd
 a
ge
. M
od
el
s a
dju
ste
d f
or 
ge
nd
er,
 
ra
ce
, 
fu
nc
tio
na
l s
ta
tu
s, 
to
ba
cc
o 
us
e,
 h
yp
er
te
ns
io
n 
an
d 
re
cr
ui
tm
en
t s
ite
. 
A
CS
 m
od
el
s w
er
e 
ad
jus
ted
 fo
r ty
pe
 of
 A
CS
 d
ia
gn
os
is.
*
p<
0.
05
*
*
p<
0.
01
*
*
*
p<
0.
00
1
A
CS
: a
cu
te
 c
or
on
ar
y 
sy
nd
ro
m
e;
 O
R:
 o
dd
s r
at
io
; C
I: 
co
nf
id
en
ce
 in
te
rv
al
; C
CI
: C
ha
rls
on
 C
om
or
bi
di
ty
 In
de
x
.
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